ENB Therapeutics

📍 New York, United States🗓 Founded 2015👥 9 employees💰 Last funded Sep 2018
Pharmaceutical Manufacturing🌐 enbpharma.com
Website LinkedIn
ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Our lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market.
5
Total investors
2
Early stage
3
Mid stage
0
Late stage
2015
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
4
Investor activity2017–2018 · investors recorded per year
2017220183
Recent (last 2y)Earlier
Frequently asked questions
Who invested in ENB Therapeutics?
ENB Therapeutics has 5 investors on record on gritt.io, including 2 early-stage backers, 3 mid-stage.
When did ENB Therapeutics last raise funding?
The most recent investment in ENB Therapeutics recorded on gritt.io was in September 2018.
When was ENB Therapeutics founded?
ENB Therapeutics was founded in 2015.
What industry is ENB Therapeutics in?
ENB Therapeutics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is ENB Therapeutics based?
ENB Therapeutics is headquartered in New York, United States.